In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Sanofi launches $69 per share bid for Genzyme; $17.5bn value

Executive Summary

Confirming speculation that began over a month ago, Sanofi-Aventis has made public a non-binding offer to acquire Genzyme Corp. The Big Pharma says it will pay $69 for each of Genzyme's outstanding shares, valuing the deal at about $17.5bn. Genzyme's board was quick to reject the offer, claiming that it dramatically undervalues the company.
Deal Industry
  • Pharmaceuticals
  • Medical Devices
    • Biomaterials
  • In Vitro Diagnostics
    • Molecular Diagnostics & Genetic Testing
  • Biotechnology
    • Gene Therapy, Cell Therapy
    • Large Molecule
Deal Status
  • Final
Deal Type
  • Acquisition
    • Full Acquisition
    • Includes Contract
    • Includes Earnout
    • Payment Includes Cash

Related Companies